Company intelligence / Profile preview

Prellis Biologics

San Francisco, California, United Statesprellisbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Prellis Biologics has developed a platform for antibody discovery using bioprinted lymph node organoids (LNO™) that recapture human immune biology. The company has previously generated 300 human antibodies that bind to the SARS-CoV2 virus.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies
Industry: Biotech

Partnerships

SanofiBristol Myers Squibb

Beyond the preview

Go deeper on Prellis Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prellis Biologics.

Explore the full profile